CTOs on the Move

Radiant Pain Relief Centres

www.radiantpainrelief.com

 
Our mission is to change people’s lives by reducing pain and offering services and support to enhance wellness, vitality and prosperity. Radiant Health Management owns and runs progressive, profitable treatment centers that offer cutting-edge therapies and services that improve people’s lives by reducing pain and restoring hope and function. Our Radiant Pain Relief Centres offer a highly refined and patient centered care model, built around an exclusive FDA-cleared pain treatment technology that create significant and lasting pain relief without drugs, needles or surgery.
  • Number of Employees: 0-25
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Aurident Inc

Aurident Inc is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AOR Canada Advanced Orthomolecular Research Inc

AOR Canada Advanced Orthomolecular Research Inc is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PaxeraMed

PaxeraMed Corp. is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NCH Healthcare System

The NCH Healthcare System is a not-for-profit multi-facility healthcare system located in Naples, Florida. The system includes two hospitals (NCH Healthcare System – Downtown Naples Hospital and NCH Healthcare System – North Naples Hospital) with a total of 681 beds collaborating with 630 physicians to care for more than 32,000 patients each year. Outpatient facilities include Walk-in Centers, Wellness Centers, Rehabilitation Centers, Wound Care Facilities, and Infusion Centers in Naples, North Naples, Marco Island, Bonita Springs, and Estero. NCH`s Emergency Departments and outpatient facilities had over 120,000 visits for the past two years. Caring for all ages in the communities it serves, NCH performs almost 500 open heart surgeries and 3,400 newborn deliveries each year.

Elcelyx Therapeutics

lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.